These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38265736)

  • 1. Incorporating Prior Data in Quantitative Benefit-Risk Assessments: Case Study of a Bayesian Method.
    Dharmarajan S; Yuan Z; Chen YF; Lackey L; Mukhopadhyay S; Singh P; Tiwari R
    Ther Innov Regul Sci; 2024 May; 58(3):415-422. PubMed ID: 38265736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A simple way to unify multicriteria decision analysis (MCDA) and stochastic multicriteria acceptability analysis (SMAA) using a Dirichlet distribution in benefit-risk assessment.
    Saint-Hilary G; Cadour S; Robert V; Gasparini M
    Biom J; 2017 May; 59(3):567-578. PubMed ID: 28187230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease: A Subanalysis of the COMPASS Randomized Clinical Trial.
    Kaplovitch E; Eikelboom JW; Dyal L; Aboyans V; Abola MT; Verhamme P; Avezum A; Fox KAA; Berkowitz SD; Bangdiwala SI; Yusuf S; Anand SS
    JAMA Cardiol; 2021 Jan; 6(1):21-29. PubMed ID: 32997098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Rivaroxaban Therapy for Patients With Peripheral Artery Disease: A Systematic Review and Meta-Analysis.
    Hao Y; Han W; Mou D; Wang J
    Vasc Endovascular Surg; 2021 Oct; 55(7):712-720. PubMed ID: 34032469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. External applicability of the COMPASS trial: the Western Denmark Heart Registry.
    Würtz M; Olesen KKW; Thim T; Kristensen SD; Eikelboom JW; Maeng M
    Eur Heart J Cardiovasc Pharmacother; 2019 Oct; 5(4):192-199. PubMed ID: 30916315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
    Anand SS; Bosch J; Eikelboom JW; Connolly SJ; Diaz R; Widimsky P; Aboyans V; Alings M; Kakkar AK; Keltai K; Maggioni AP; Lewis BS; Störk S; Zhu J; Lopez-Jaramillo P; O'Donnell M; Commerford PJ; Vinereanu D; Pogosova N; Ryden L; Fox KAA; Bhatt DL; Misselwitz F; Varigos JD; Vanassche T; Avezum AA; Chen E; Branch K; Leong DP; Bangdiwala SI; Hart RG; Yusuf S;
    Lancet; 2018 Jan; 391(10117):219-229. PubMed ID: 29132880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Editor's Choice - External Applicability of the COMPASS and VOYAGER-PAD Trials on Patients with Symptomatic Lower Extremity Artery Disease in France: The COPART Registry.
    Lapébie FX; Aboyans V; Lacroix P; Constans J; Boulon C; Messas E; Ferrières J; Bongard V; Bura-Rivière A
    Eur J Vasc Endovasc Surg; 2021 Sep; 62(3):439-449. PubMed ID: 34330647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
    Connolly SJ; Eikelboom JW; Bosch J; Dagenais G; Dyal L; Lanas F; Metsarinne K; O'Donnell M; Dans AL; Ha JW; Parkhomenko AN; Avezum AA; Lonn E; Lisheng L; Torp-Pedersen C; Widimsky P; Maggioni AP; Felix C; Keltai K; Hori M; Yusoff K; Guzik TJ; Bhatt DL; Branch KRH; Cook Bruns N; Berkowitz SD; Anand SS; Varigos JD; Fox KAA; Yusuf S;
    Lancet; 2018 Jan; 391(10117):205-218. PubMed ID: 29132879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland.
    Soini E; Virtanen O; Väätäinen S; Briere JB; Bowrin K; Millier A
    Adv Ther; 2020 Jul; 37(7):3348-3369. PubMed ID: 32519113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial.
    Vanassche T; Verhamme P; Anand SS; Shestakovska O; Fox KA; Bhatt DL; Avezum A; Alings M; Aboyans V; Maggioni AP; Widimsky P; Berkowitz SD; Yusuf S; Connolly SJ; Eikelboom JW; Bosch J
    Eur J Prev Cardiol; 2020 Feb; 27(3):296-307. PubMed ID: 31615291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Bayesian approach for individual-level drug benefit-risk assessment.
    Li K; Luo S; Yuan S; Mt-Isa S
    Stat Med; 2019 Jul; 38(16):3040-3052. PubMed ID: 30989691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VOYAGER PAD contributes to medical therapy for peripheral artery disease.
    Farber A
    J Vasc Surg; 2020 Dec; 72(6):1843-1844. PubMed ID: 33222822
    [No Abstract]   [Full Text] [Related]  

  • 13. Network Meta-analysis of the Benefit of Aspirin with Rivaroxaban vs. Clopidogrel for Patients with Stable Symptomatic Lower Extremity Arterial Disease.
    Ambler GK; Nordanstig J; Behrendt CA; Twine CP
    Eur J Vasc Endovasc Surg; 2021 Oct; 62(4):654-655. PubMed ID: 34452837
    [No Abstract]   [Full Text] [Related]  

  • 14. The Voyager PAD Trial - New Path for Post-revascularisation PAD Patients.
    Debus ES; Nehler MR;
    Eur J Vasc Endovasc Surg; 2020 May; 59(5):699-700. PubMed ID: 32307302
    [No Abstract]   [Full Text] [Related]  

  • 15. Health economic evaluation of rivaroxaban in the treatment of patients with chronic coronary artery disease or peripheral artery disease.
    Cowie MR; Lamy A; Levy P; Mealing S; Millier A; Mernagh P; Cristeau O; Bowrin K; Briere JB
    Cardiovasc Res; 2020 Sep; 116(11):1918-1924. PubMed ID: 31807773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of Xa inhibitors in patients with heart failure and coronary or peripheral artery disease: a systematic review and meta-analysis of randomized controlled trials.
    Chen Y; Feng X; Qi C; Zhou L; Sun Y; Gu Z; Li X
    Ann Palliat Med; 2021 Jul; 10(7):8082-8093. PubMed ID: 34353093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rivaroxaban in Peripheral Artery Disease after Revascularization.
    Bonaca MP; Bauersachs RM; Anand SS; Debus ES; Nehler MR; Patel MR; Fanelli F; Capell WH; Diao L; Jaeger N; Hess CN; Pap AF; Kittelson JM; Gudz I; Mátyás L; Krievins DK; Diaz R; Brodmann M; Muehlhofer E; Haskell LP; Berkowitz SD; Hiatt WR
    N Engl J Med; 2020 May; 382(21):1994-2004. PubMed ID: 32222135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of low-dose anticoagulation therapy on peripheral artery disease: insights from the VOYAGER trial.
    Fukaya E; Leeper NJ
    Cardiovasc Res; 2020 Oct; 116(12):e156-e158. PubMed ID: 32980875
    [No Abstract]   [Full Text] [Related]  

  • 19. Cost-effectiveness of low-dose rivaroxaban and aspirin versus aspirin alone in people with peripheral or carotid artery disease: An Australian healthcare perspective.
    Zomer E; Si S; Hird TR; Liew D; Owen AJ; Tonkin A; Reid CM; Ademi Z
    Eur J Prev Cardiol; 2019 May; 26(8):858-868. PubMed ID: 30526023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Revascularisation for Symptomatic Peripheral Artery Disease: External Applicability of the VOYAGER PAD Trial.
    Søgaard M; Nielsen PB; Skjøth F; Larsen TB; Eldrup N
    Eur J Vasc Endovasc Surg; 2022 Feb; 63(2):285-294. PubMed ID: 34924303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.